Basilea's expertise in oncology is clearly growing, benefiting from a strategy to identify those patients best suited to respond across the oncology pipeline. This is particularly important in previously intractable cancers where an all-comers approach elsewhere has been beset with disappointment and failure. One of the most challenging cancers remains brain cancer and glioblastoma multiforme in particular. Attempts to develop effective treatments have been largely unsuccessful, but the observation that patients receiving lisavanbulin have derived significant benefit is potentially transformational for relevant patients.
06 Jul 2021
Lisavanbulin – showing lots of promise
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Lisavanbulin – showing lots of promise
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
06 Jul 2021 -
Author:
Brian White | Andrew Keith -
Pages:
16
Basilea's expertise in oncology is clearly growing, benefiting from a strategy to identify those patients best suited to respond across the oncology pipeline. This is particularly important in previously intractable cancers where an all-comers approach elsewhere has been beset with disappointment and failure. One of the most challenging cancers remains brain cancer and glioblastoma multiforme in particular. Attempts to develop effective treatments have been largely unsuccessful, but the observation that patients receiving lisavanbulin have derived significant benefit is potentially transformational for relevant patients.